External beam radiotherapy dose response of prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 39, Issue 5, 1997, Pages 1011-1018

  Pollack, Alan ^a,b   Zagars, Gunar K ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Dose; Prostate specific antigen; Radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; RADIATION DOSE; RELAPSE; SCORING SYSTEM; TREATMENT FAILURE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0030661678     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(97)00508-7     Document Type: Article

References (18)

1. Cox, D. R.; Oakes, D. Analysis of survival data. London: Chapman and Hall; 1984:110-120.
2. Hanks, G. E.; Lee, W. R.; Hanlon, A. L.; Hunt, M. S.; Kaplan, E.; Epstein, B. E.; Movsas, B.; Schultheiss, T. E. Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥10 ng/ ml. Int. J. Radiat. Oncol. Biol. Phys. 35:861-868; 1996.
3. Hanks, G. E.; Leibel, S. Q.; Krall, J. M.; Kramer, S. Patterns of care studies: Dose-response observations for local control of adenocarcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 11:153-157; 1985.
4. Hanks, G. E.; Schultheiss, T. E.; Hanlon, H. A.; Hunt, M.; Lee, W. R.; Epstein, B. E.; Coia, L. R. Optimization of conformal radiation treatment of prostate cancer: Report of a dose escalation study. Int. J. Radiat. Oncol. Biol. Phys. 37: 543-555; 1997.
5. Hanks, G. E.; Martz, K. L.; Diamond, J. J. The effect of dose on local control of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 15:1299-1305; 1988.
6. Harris, E. K.; Albert, A. Survivorship analysis for clinical studies. New York: Marcel Dekker, Inc.; 1991:5-125.
7. Perez, C. A.; Pilepich, M. V.; Garcia, D.; Simpson, J. R.; Zivnuska, F.; Hederman, M. A. Definitive radiation therapy in carcinoma of the prostate localized to the pelvis: Experience at the Mallinckrodt Institute of Radiology. NCI Monogr. 7:85-94; 1988.
8. Perez, C. A.; Walz, B. J.; Zivnuska, F. R.; Pilepich, M.; Prasad, K.; Bauer, W. Irradiation of carcinoma of the prostate localized to the pelvis: Analysis of tumor response and prognosis. Int. J. Radiat. Oncol. Biol. Phys. 6:555-563; 1980.
9. Pollack, A.; Lankford, S.; Zagars, G. K.; Babaian, R. J. PSA density as a prognostic factor in prostate cancer patients treated with radiotherapy. Cancer 77:1515-1523; 1996.
10. Pollack, A.; Zagars, G. K.; Starkschall, G.; Childress, C. H.; Kopplin, S.; Boyer, A. L.; Rosen, I. I. Conventional versus conformal radiotherapy for prostate cancer: Preliminary results of dosimetry and acute toxicity. Int. J. Radiat. Oncol. Biol. Phys. 34:555-564; 1996.
11. Roach, M., III; Burton, E.; Kroll, S.; Bevins, S.; Ryu, J. K.; Holland, J. M.; Hunter, D. C.; Rosenthal, S.; Margolis, L. W.; Phillips, T. L. 501 men irradiated for clinically localized prostate cancer (1987-1995): Preliminary analysis of the experience at UCSF and affiliated facilities. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 36:248; 1996.
12. Roy, A. V.; Bower, M. E.; Hayden, J. E. Sodium thymolphthalein monophosphate: A new acid phosphatase substrate with greater specificity for the prostatic enzyme inserum. Clin. Chem. 17:1093-1102; 1971.
13. Shipley, W. U.; Verhey, L. J.; Munzenrider, J. E.; Suit, H. D.; Urie, M. M.; McManus P. L.; Young, R. H.; Shipley, J. W.; Zietman, A. L.; Biggs, P. J.; Heney, N. M.; Goitein, M. Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int. J. Radiat. Oncol. Biol. Phys. 32:3-12; 1995.
14. Zagars, G. K. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 23:47-53; 1992.
15. Zagars, G. K.; Kavadi, V. S.; Pollack, A.; von Eschenbach, A. C.; Sands, M. E. The source of pre-treatment serum prostate-specific antigen in clinically localized prostate cancer - T, N, or M? Int. J. Radiat. Oncol. Biol. Phys. 32:21-32; 1995.
16. Zagars, G. K.; Pollack, A.; von Eschenbach, A. C. Prostate cancer and radiation therapy - The message conveyed by serum prostate-specific antigen. Int. J. Radiat. Oncol. Biol. Phys. 33:23-25; 1995.
17. Zagars, G. K.; Pollack, A.; von Eschenbach, A. C. Prognostic factors in clinically localized prostate cancer - Analysis of 938 patients irradiated in the PSA era. Cancer 79:1370-1380; 1997.
18. Zelefsky, M. J.; Leibel, S. A.; Kelson, S.; Fuks, Z. Impact of radiation dose on achieving nadir PSA levels after 3-dimensional conformal radiotherapy for patients with localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. Suppl 36:196; 1996.